Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients

Lung Cancer

Volumn 51, Issue 3, 2006, Pages 303-311

  Gautschi, Oliver ^a   Hugli, Barbara ^a   Ziegler, Annemarie ^b   Bigosch, Colette ^b   Bowers, Naomi L ^c   Ratschiller, Daniel ^a   Jermann, Monika ^b   Stahel, Rolf A ^b   Heighway, Jim ^d   Betticher, Daniel C ^e  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d Cancer Communications and Consultancy Ltd   (United Kingdom)

^e Hopital Cantonal de Fribourg   (Switzerland)

Author keywords

Chemotherapy; Cyclin D1; Gene polymorphism; Lung cancer; Predictive factor; Smoking

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLIN D1; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CISPLATIN; CYCLIN D1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SMOKING; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 33144459620     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.10.025     Document Type: Article

References (48)

1. A.J. Alberg, and J.M. Samet Epidemiology of lung cancer Chest 123 1 Suppl. 2003 21S 49S
2. F.P. Perera, L.A. Mooney, M. Stampfer, D.H. Phillips, D.A. Bell, and A. Rundle Associations between carcinogen-DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians' Health Cohort Study Carcinogenesis 23 10 2002 1641 1646
3. L.E. Mechanic, A.J. Marrogi, J.A. Welsh, E.D. Bowman, M.A. Khan, and L. Enewold Polymorphisms in XPD and TP53 and mutation in human lung cancer Carcinogenesis 26 3 2005 597 604
4. S. Benhamou, and A. Sarasin ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review Am J Epidemiol 161 1 2005 1 14
5. G. D'Addario, M. Pintilie, N.B. Leighl, R. Feld, T. Cerny, and F.A. Shepherd Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature J Clin Oncol 23 13 2005 2926 2936
6. M. Reck, and U. Gatzemeier Chemotherapy in stage-IV NSCLC Lung Cancer 45 Suppl. 2 2004 S217 S222
7. R. Rosell, M. Taron, and A. O'Brate Predictive molecular markers in non-small cell lung cancer Curr Opin Oncol 13 2 2001 101 109
8. J.R. Fischer, and H. Lahm Validation of molecular and immunological factors with predictive importance in lung cancer Lung Cancer 45 Suppl. 2 2004 S151 S161
9. O. Coqueret Linking cyclins to transcriptional control Gene 299 1-2 2002 35 55
10. A. Arnold, H.G. Kim, R.D. Gaz, R.L. Eddy, Y. Fukushima, and M.G. Byers Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma J Clin Invest 83 6 1989 2034 2040
11. E. Schuuring, E. Verhoeven, W.J. Mooi, and R.J. Michalides Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas Oncogene 7 2 1992 355 361
12. H. Matsushime, M.F. Roussel, R.A. Ashmun, and C.J. Sherr Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle Cell 65 4 1991 701 713
13. T. Motokura, and A. Arnold PRAD1/cyclin D1 proto-oncogene: genomic organization, 5′ DNA sequence, and sequence of a tumor-specific rearrangement breakpoint Genes Chromosomes Cancer 7 2 1993 89 95
14. V. Fantl, M.A. Richards, R. Smith, G.A. Lammie, G. Johnstone, and D. Allen Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer Eur J Cancer 26 4 1990 423 429
15. M.F. Buckley, K.J. Sweeney, J.A. Hamilton, R.L. Sini, D.L. Manning, and R.I. Nicholson Expression and amplification of cyclin genes in human breast cancer Oncogene 8 8 1993 2127 2133
16. S.W. Tam, A.M. Theodoras, J.W. Shay, G.F. Draetta, and M. Pagano Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for cyclin D1 function in G1 progression Oncogene 9 9 1994 2663 2674
17. K. Maeda, Y. Chung, S. Kang, M. Ogawa, N. Onoda, and Y. Nishiguchi Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma Oncology 55 2 1998 145 151
18. D.C. Betticher, J. Heighway, P.S. Hasleton, H.J. Altermatt, W.D. Ryder, and T. Cerny Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer Br J Cancer 73 3 1996 294 300
19. D.C. Betticher, N. Thatcher, H.J. Altermatt, P. Hoban, W.D. Ryder, and J. Heighway Alternate splicing produces a novel cyclin D1 transcript Oncogene 11 5 1995 1005 1011
20. S. Qiuling, Z. Yuxin, Z. Suhua, X. Cheng, L. Shuguang, and H. Fengsheng Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population Carcinogenesis 24 9 2003 1499 1503
21. O. Gautschi, C. Bigosch, B. Huegli, M. Jermann, A. Marx, and E. Chasse Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy J Clin Oncol 22 20 2004 4157 4164
22. X.O. Shu, D.B. Moore, Q. Cai, J. Cheng, and W. Wen Association of cyclin D1 genotype with breast cancer risk and survival Cancer Epidemiol Biomarkers Prev 14 1 2005 91 97
23. C. Matthias, K. Branigan, V. Jahnke, K. Leder, J. Haas, and J. Heighway Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck Clin Cancer Res 4 10 1998 2411 2418
24. S.L. Holley, G. Parkes, C. Matthias, U. Bockmuhl, V. Jahnke, and K. Leder Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck Am J Pathol 159 5 2001 1917 1924
25. Y. Zheng, H. Shen, E.M. Sturgis, L.E. Wang, S.A. Eicher, and S.S. Strom Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study Carcinogenesis 22 8 2001 1195 1199
26. S.L. Holley, C. Matthias, V. Jahnke, A.A. Fryer, R.C. Strange, and P.R. Hoban Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma Oral Oncol 41 2 2005 156 160
27. K.K. Dhar, K. Branigan, R.E. Howells, C. Musgrove, P.W. Jones, and R.C. Strange Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancer Int J Gynecol Cancer 9 4 1999 342 347
28. L. Wang, T. Habuchi, T. Takahashi, K. Mitsumori, T. Kamoto, and Y. Kakehi Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer Carcinogenesis 23 2 2002 257 264
29. L. Le Marchand, A. Seifried, A. Lum-Jones, T. Donlon, and L.R. Wilkens Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer JAMA 290 21 2003 2843 2848
30. H. Koike, K. Suzuki, T. Satoh, N. Ohtake, T. Takei, and S. Nakata Cyclin D1 gene polymorphism and familial prostate cancer: the AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage Anticancer Res 23 6D 2003 4947 4951
31. J. Yu, T. Habuchi, N. Tsuchiya, E. Nakamura, H. Kakinuma, and Y. Horikawa Association of the cyclin D1 gene G870a polymorphism with susceptibility to sporadic renal cell carcinoma J Urol 172 6, Part 1 of 2 2004 2410 2413
32. S. Buch, B. Zhu, A.G. Davis, D. Odom, J.M. Siegfried, and J.R. Grandis Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract Mol Carcinog 42 4 2005 222 228
33. F. Grieu, S. Malaney, R. Ward, D. Joseph, and B. Iacopetta Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers Anticancer Res 23 5b 2003 4257 4259
34. J.A. McKay, J. Githang'a, A. Indalo, T. Li, X. Liu, and M. Ameyaw Distinct differences in a cyclin D1 single nucleotide polymorphism between ethnic groups GeneScreen 1 1 2001 139 142
35. S.L. Holley, J. Heighway, and P.R. Hoban Induced expression of human CCND1 alternative transcripts in mouse Cyl-1 knockout fibroblasts highlights functional differences Int J Cancer 114 3 2005 364 370
36. M. Gugger, A. Kappeler, S. Vonlanthen, H.J. Altermatt, H.B. Ris, and D. Lardinois Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours Lung Cancer 33 2-3 2001 229 239
37. L. Burke, D.B. Flieder, D.G. Guinee, E. Brambilla, A.N. Freedman, and W.P. Bennett Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma Clin Cancer Res 11 1 2005 232 241
38. D. Ratschiller, J. Heighway, M. Gugger, A. Kappeler, F. Pirnia, and R.A. Schmid Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival J Clin Oncol 21 11 2003 2085 2093
39. G.S. Omenn, G.E. Goodman, M.D. Thornquist, J. Balmes, M.R. Cullen, and A. Glass Effects of a combination of beta carotene and Vitamin A on lung cancer and cardiovascular disease N Engl J Med 334 18 1996 1150 1155
40. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group The effect of Vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers N Engl J Med 330 15 1994 1029 1035
41. N. Sueoka, H.Y. Lee, G.L. Walsh, W.K. Hong, and J.M. Kurie Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells Cancer Res 59 15 1999 3838 3844
42. S. Vonlanthen, J. Heighway, A. Kappeler, H.J. Altermatt, M.M. Borner, and D.C. Betticher p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer Int J Oncol 16 5 2000 951 957
43. T. Nakashima, and G.L. Clayman Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma Arch Otolaryngol Head Neck Surg 126 8 2000 957 961
44. R.V. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, and M. Domine Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin Cancer Res 8 7 2002 2286 2291
45. C. Dumontet, S. Isaac, P.J. Souquet, F. Bejui-Thivolet, Y. Pacheco, and N. Peloux Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy Bull Cancer 92 2 2005 E25 E30
46. J.D. Davidson, L. Ma, M. Flagella, S. Geeganage, L.M. Gelbert, and C.A. Slapak An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines Cancer Res 64 11 2004 3761 3766
47. R. Rosell, M. Taron, J.M. Sanchez, T. Moran, N. Reguart, and B. Besse The promise of pharmacogenomics: gemcitabine and pemetrexed Oncol (Huntingt) 18 13 Suppl. 8 2004 70 76
48. F.R. Hirsch, and S. Witta Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer Curr Opin Oncol 17 2 2005 118 122